{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T04:35:05Z","timestamp":1724560505359},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive fungal infections (IFIs) are the most frequent cause of morbidity and mortality in immunocompromised children. Voriconazole is the first-line antifungal choice in the treatment of IFIs like aspergillosis. Voriconazole pharmacokinetics vary widely among patients and voriconazole is metabolized mainly in the liver by the CYP2C19 enzyme, which is highly polymorphic. The <jats:italic>CYP<\/jats:italic>2<jats:italic>C19*17<\/jats:italic> allele is characterized by the presence of four single nucleotide polymorphisms expressing an ultra-rapid enzyme phenotype with an accelerated voriconazole metabolism, is associated with low (sub-therapeutic) plasma levels in patients treated with the standard dose. Considering that in our center a high percentage of children have sub-therapeutic levels of voriconazole when treated with standard doses, we sought to determine the frequency of the <jats:italic>CYP2C19*17<\/jats:italic> polymorphism (rs12248560) in a Chilean population and determine the association between voriconazole concentrations and the rs12248560 variant in immunocompromised children. First, we evaluated the frequency of the rs12248560 variant in a group of 232 healthy Chilean children, and we found that 180 children (77.6%) were non-carriers of the rs12248560 variant, 49 children (21.1%) were heterozygous carriers for rs12248560 variant and only 3 children (1.3%) were homozygous carriers for rs12248560 variant, obtaining an allelic frequency of 12% for variant in a Chilean population. To determine the association between voriconazole concentrations and the rs12248560 variant, we analyzed voriconazole plasma concentrations in a second group of 33 children treated with voriconazole. In these patients, carriers of the rs12248560 variant presented significantly lower voriconazole plasma concentrations than non-carriers (<jats:italic>p<\/jats:italic>\u2009=\u20090,011). In this study, we show the presence of the rs12248560 variant in a Chilean population and its accelerating effect on the pharmacokinetics of voriconazole in pediatric patients. From these data, it would be advisable to consider the variant of the patient prior to calculating the dosage of voriconazole.<\/jats:p>","DOI":"10.1038\/s41598-019-45345-2","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:03:04Z","timestamp":1561024984000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children"],"prefix":"10.1038","volume":"9","author":[{"given":"N.","family":"Espinoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Galdames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Navea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Farf\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"5","key":"45345_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/00365548.2011.641505","volume":"44","author":"A Zwitserloot","year":"2012","unstructured":"Zwitserloot, A. et al. Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in children. Scand J Infect Dis. 44(5), 355\u2013362, https:\/\/doi.org\/10.3109\/00365548.2011.641505 (2012).","journal-title":"Scand J Infect Dis."},{"issue":"6","key":"45345_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10096-015-2340-y","volume":"34","author":"M D\u00f6ring","year":"2015","unstructured":"D\u00f6ring, M. et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin microbiol 34(6), 1189\u20131200, https:\/\/doi.org\/10.1007\/s10096-015-2340-y (2015).","journal-title":"Eur J Clin microbiol"},{"issue":"5","key":"45345_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104","volume":"65","author":"R Baldwin","year":"2008","unstructured":"Baldwin, R. et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 65(5), 767\u2013774, https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03104 (2008).","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"45345_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.hemonc.2017.05.013","volume":"10","author":"AS Omrani","year":"2017","unstructured":"Omrani, A. S. & Almaghrabi, R. S. Complications of hematopoietic stem transplantation: Fungal infections. Hematol Oncol Stem Cell Ther. 10(4), 239\u2013244, https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.013 (2017).","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"1","key":"45345_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5863\/1551-6776-20.1.17","volume":"20","author":"L Tucker","year":"2015","unstructured":"Tucker, L. et al. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 20(1), 17\u201323, https:\/\/doi.org\/10.5863\/1551-6776-20.1.17 (2015).","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"8","key":"45345_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/pgs.14.53","volume":"15","author":"J Hicks","year":"2014","unstructured":"Hicks, J. et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics J. 15(8), 1065\u201378, https:\/\/doi.org\/10.2217\/pgs.14.53 (2014).","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"45345_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/dmd.109.029769","volume":"38","author":"SB Yanni","year":"2010","unstructured":"Yanni, S. B. et al. In Vitro metabolism explains higher clearance of voriconazole in children versus adult: role of CYP2C19 and Flavin-containing monooxygenase 3. Drug Metab and Dispos. 38(1), 25\u201331, https:\/\/doi.org\/10.1124\/dmd.109.029769 (2010).","journal-title":"Drug Metab and Dispos."},{"issue":"12","key":"45345_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","volume":"53","author":"NR Zane","year":"2014","unstructured":"Zane, N. R. & Thakker, D. R. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. Clin Pharmacokinet. 53(12), 1171\u201382, https:\/\/doi.org\/10.1007\/s40262-014-0181-y (2014).","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"45345_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/tpj.2011.5","volume":"12","author":"SA Scott","year":"2012","unstructured":"Scott, S. A. et al. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J. 12(4), 297\u2013305, https:\/\/doi.org\/10.1038\/tpj.2011.5 (2012).","journal-title":"Pharmacogenomics J."},{"issue":"3","key":"45345_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00228-008-0574-7","volume":"65","author":"G Wang","year":"2009","unstructured":"Wang, G. et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 65(3), 281\u2013285, https:\/\/doi.org\/10.1007\/s00228-008-0574-7 (2009).","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"45345_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2125.2010.03801","volume":"71","author":"M Dolton","year":"2011","unstructured":"Dolton, M. & McLachlan, A. Clinical importance of the CYP2C1917 variant allele for voriconazole. Br J Clin Pharmacol. 71(1), 137\u2013138, https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03801 (2011).","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"45345_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/INF.0000000000001339","volume":"22","author":"A Teusink","year":"2016","unstructured":"Teusink, A. et al. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 22(3), 482\u20136, https:\/\/doi.org\/10.1097\/INF.0000000000001339 (2016).","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"45345_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","volume":"27","author":"IS Hamadeh","year":"2017","unstructured":"Hamadeh, I. S. et al. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics. 27(5), 190\u2013196, https:\/\/doi.org\/10.1097\/FPC.0000000000000277 (2017).","journal-title":"Pharmacogenet Genomics."},{"issue":"2","key":"45345_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.dmpk.2015.12.005","volume":"31","author":"S Chuwongwattana","year":"2016","unstructured":"Chuwongwattana, S. et al. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug Metab Pharmacokinet. 31(2), 117\u201322, https:\/\/doi.org\/10.1016\/j.dmpk.2015.12.005 (2016).","journal-title":"Drug Metab Pharmacokinet."},{"issue":"1","key":"45345_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.DMPK-12-RV-085","volume":"28","author":"T Hirota","year":"2013","unstructured":"Hirota, T., Eguchi, S. & Ieiri, I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 28(1), 28\u201337 (2013).","journal-title":"Drug Metab Pharmacokinet."},{"issue":"5","key":"45345_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/cpt.1012","volume":"104","author":"N Mangal","year":"2018","unstructured":"Mangal, N. et al. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. Clin Pharmacol Ther. 104(5), 957\u2013965, https:\/\/doi.org\/10.1002\/cpt.1012 (2018).","journal-title":"Clin Pharmacol Ther."},{"issue":"7","key":"45345_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","volume":"47","author":"G Pennick","year":"2003","unstructured":"Pennick, G., Clark, M., Sutton, D. & Rinaldi, M. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 47(7), 2348\u201350, https:\/\/doi.org\/10.1128\/AAC.47.7.2348-2350.2003 (2003).","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"45345_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","volume":"84","author":"SP Myrand","year":"2008","unstructured":"Myrand, S. P. et al. Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 84(3), 347\u201361, https:\/\/doi.org\/10.1038\/sj.clpt.6100482 (2008).","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"45345_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2016","unstructured":"Moriyama, B. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 102(1), 45\u201351, https:\/\/doi.org\/10.1002\/cpt.583 (2016).","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"45345_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s11033-013-2971-y","volume":"41","author":"J Vicente","year":"2014","unstructured":"Vicente, J. et al. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: A comparative study. Mol Biol Rep. 41(3), 1267\u20131272, https:\/\/doi.org\/10.1007\/s11033-013-2971-y (2014).","journal-title":"Mol Biol Rep."},{"issue":"318","key":"45345_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2012.00318","volume":"3","author":"S Lee","year":"2013","unstructured":"Lee, S. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 3(318), 1\u20137, https:\/\/doi.org\/10.3389\/fgene.2012.00318 (2013).","journal-title":"Front Genet."},{"issue":"5","key":"45345_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s11096-015-0143-y","volume":"37","author":"P Chawla","year":"2015","unstructured":"Chawla, P. et al. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. Int J Clin Pharm. 37(5), 925\u2013930, https:\/\/doi.org\/10.1007\/s11096-015-0143-y (2015).","journal-title":"Int J Clin Pharm."},{"issue":"14","key":"45345_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.2174\/1389200219666171227200547","volume":"19","author":"X Zhong","year":"2018","unstructured":"Zhong, X., Tong, X., Ju, Y., Du, X. & Li, Y. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision? Curr Drug Metab. 19(14), 1152\u20131158, https:\/\/doi.org\/10.2174\/1389200219666171227200547 (2018).","journal-title":"Curr Drug Metab."},{"issue":"11","key":"45345_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/pgs-2017-0173","volume":"19","author":"S Allegra","year":"2018","unstructured":"Allegra, S. et al. Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics J. 19(11), 913\u2013925, https:\/\/doi.org\/10.2217\/pgs-2017-0173 (2018).","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"45345_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bcp.13401","volume":"84","author":"S Allegra","year":"2018","unstructured":"Allegra, S. et al. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol. 84(1), 197\u2013203, https:\/\/doi.org\/10.1111\/bcp.13401 (2018).","journal-title":"Br J Clin Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45345-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:30:09Z","timestamp":1671273009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45345"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45345-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8863"}}